Challenges in the development of companion diagnostics for neuropsychiatric disorders.
There are few examples of successful CNS diagnostics owing to our poor understanding of the mechanisms of disease. This article will discuss this and other challenges facing CNS diagnostic development with a focus on Alzheimer's disease, along with a discussion of potential future diagnostic assays that may help in the development of new CNS medications.
Pharma Research and Early Development CNS Biomarkers Section, F. Hoffmann-La Roche, CH-4070 Basel, Switzerland. tania.nikolcheva@roche.com
Tania
T
Nikolcheva
Stephan
S
Jäger
Theresa Ambrose
TA
Bush
Gabriel
G
Vargas
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000473:pathology; D015415:Biomarkers; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis*; D025202:Molecular Diagnostic Techniques / Q000379:methods*
D015415:Biomarkers